ST. LOUIS, April 02, 2025 (GLOBE NEWSWIRE) -- Curium announced today that the U.S. Food and Drug Administration approved its generic version of the Kit for the Preparation of Technetium Tc 99m ...
PARIS, March 28, 2025 (GLOBE NEWSWIRE) -- Curium Pharma (“Curium”), a world leader in nuclear medicine, is pleased to announce the completion of its acquisition of Eczacıbaşı-Monrol Nuclear Products ...
The MarketWatch News Department was not involved in the creation of this content. -- Curium and CapVest have announced the recapitalization of Curium via a new Continuation Vehicle -- The transaction ...
The acquisition of Nucleis will: Enhance Curium's PET manufacturing capacity and radiopharmaceutical distribution network of 32 PET sites in Western Europe Improve reliability and accessibility of ...
Primary staging of patients with high-risk PCa prior to initial curative therapy To localize recurrence of PCa in patients with a suspected recurrence based on increasing serum prostate-specific ...
PARIS, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that in Estonia, Finland, Latvia, and Sweden, PYLCLARI® is now available for patients with prostate ...
Positions Curium as leading manufacturer of Lu-177 isotope Brings innovative R&D expertise and pipeline to Curium Enhances Curium’s SPECT & PET geographical coverage and supply chain PARIS, March 28, ...
The acquisition enhances Curium’s manufacturing capacity of Lutetium-177 (Lu-177) to meet the growing demand for isotope around the world and secure the supply for the future launch of Curium’s Lu-177 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results